Lobe Sciences announces the PCT (Patent Cooperation Treaty) patent application for their method of treating mTBI and PTSD.
Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”) is pleased to announce its patent-pending therapeutic regimen that has been designed for treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder, and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder has been published by the World Intellectual Property Organization.
Philip Young, CEO & Director, commented, “The publication of our PCT patent application demonstrates our continued commitment to developing novel treatments for diseases where there is no approved treatment. Our partners at the University of Miami are continuing to run in vivo tests on these patent-pending combination therapies. I look forward to updating the investor community on our progress and plans for 2022.”
The Company also announced today the resignation of Leighton Bocking from its Board of Directors for personal reasons. The Company wishes to thank Leighton for his many years of service and contributions during his tenure as a Director of the Company. The Company will immediately begin a search for a new independent board member to replace Leighton.
Companies Featured
Lobe SciencesLobe Sciences is a listed (CSE) Canadian company with a focus on treating traumatic brain injury (TBI). It is led by pioneering scientists, engineers, and physicians focused on investigating, researching and developing treatments for brain health through alternative and nontraditional medicines and the latest technologies.